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NO reactions with hemoglobin (Hb) likely play a role
in blood pressure regulation. For example, NO exchange
between Hb and S-nitrosoglutathione (GSNO) has been
reported in vitro. Here we examine the reaction between
GSNO and deoxyHb (HbFeII) in the presence of both
Cu(I) (2,9-dimethyl-1, 10-phenanthroline (neocuproine))
and Cu(II) (diethylenetriamine-N,N,N,N,N-pentaace-
tic acid) chelators using a copper-depleted Hb solution.
Spectroscopic analysis of deoxyHb (HbFeII)/GSNO incu-
bates shows prompt formation (<5 min) of 100% heme-
nitrosylated Hb (HbFeIINO) in the absence of chelators,
46% in the presence of diethylenetriamine-N,N,N,N,N-
pentaacetic acid, and 25% in the presence of neocu-
proine. Negligible (<2%) HbFeIINO was detected when
neocuproine was added to copper-depleted HbFeII/
GSNO incubates. Thus, HbFeIINO formation via a mech-
anism involving free NO generated by Cu(I) catalysis of
GSNO breakdown is proposed. GSH is a source of reduc-
ing equivalents because extensive GSSG was detected in
HbFeII/GSNO incubates in the absence of metal chela-
tors. No S-nitrosation of HbFeII was detected under any
conditions. In contrast, the NO released from GSNO is
directed to Cys93 of oxyHb in the absence of chelators,
but only metHb formation is observed in the presence of
chelators. Our findings reveal that the reactions of
GSNO and Hb are controlled by copper and that metal
chelators do not fully inhibit NO release from GSNO in
Hb-containing solutions.
Possible exchange of NO between thiols and hemoglobin
(Hb)1 in red blood cells (RBCs) has been the focus of intense
interest recently (1, 2). It has been suggested that GSNO or
S-nitroso-L-cysteinyl could act as an NO donor to Cys93 of
oxyhemoglobin (HbFeIIO2) in a trans-S-nitrosation reaction (3).
However, we have shown that free NO must first be released
from GSNO (4), the S-nitroso form of the dominant thiol in the
RBC (5), or S-nitroso-L-cysteinyl2 in a Cu(I)-catalyzed reaction.
S-Nitrosation of Cys93 then occurs in a Cu(II)-catalyzed reac-
tion (4) as reported also for Cys34 of bovine serum albumin (6).
For Hb to function as a blood pressure regulator in an O2-
sensitive manner, release of NO from Cys93 of HbFeII is nec-
essary (7). One possibility is that NO is delivered to tissues via
S-nitrosation from Cys93 to GSH or another thiol (8) that
promotes NO transport across the RBC.
HbSNO  RSHº HbSH  RSNO
REACTION 1
Recently it has been suggested that delivery to tissues of all
of the NO bound to Cys93 of Hb would result in extensive
vasodilation, which would be fatal (9). Hence, it was proposed
that most of the NO released from Cys93 is actually captured
by HbFeII. Capture of NO released from GSNO is also possible
and would compete with the exit of NO from the RBC. In fact,
Spencer et al. (10) reported direct reductive cleavage of GSNO
by HbFeII and capture of the released NO by another FeII
center (HbFeII).
HbFeII  GSNO  Hº HbFeIII  GSH  NO
HbFeII  NOº HbFeIINO
REACTIONS 2 AND 3
A trace amount of Cu(I) serves as a highly efficient catalyst
of S-nitrosothiol breakdown (11). We have suggested that neo-
cuproine, a Cu(I)-specific chelator, inhibits NO release from
GSNO in solutions of HbFeIIO2 (4). Therefore, we considered it
likely that neocuproine would also inhibit NO release from
GSNO in solutions containing HbFeII. To distinguish between
direct reductive cleavage of GSNO by HbFeII (Reaction 2) and
Cu(I)-catalyzed release (Reaction 4), it is necessary to remove
all trace copper or prevent its turnover via redox cycling using
GSH (Reaction 5) or another donor in the Hb-containing
solutions.
Cu(I)  GSNO  Hº Cu(II)  GSH  NO
Cu(II)  GSHº Cu(I)  1⁄2 GSSG  H
REACTIONS 4 AND 5
Here we report the results of a detailed examination of
HbFeII/GSNO incubates after 5 min in the presence of prefer-
ential chelators of Cu(I) (neocuproine) and Cu(II) (DTPA). So-
lutions of HbFeII that were not dialyzed and solutions that
underwent exhaustive dialysis versus EDTA were used. Our
direct spectroscopic and ESI-MS analyses reveal that NO re-
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lease from GSNO is 2% in the presence of neocuproine in
HbFeII/GSNO solutions containing dialyzed Hb. HbFeIINO for-
mation, and hence GSNO breakdown, is 100% within 5 min
in the absence of chelators. HbFeIINO formation is decreased
by 50–75% in the presence of DTPA and neocuproine and in
solutions containing dialyzed Hb without neocuproine. Because
trace copper was found in all reagents by ICP-MS, these obser-
vations are consistent with Cu(I)-catalyzed release of NO
(Reaction 4).
The source of the reducing equivalents for the prompt Cu(I)-
catalyzed reductive cleavage of GSNO is also of interest. Ex-
tensive GSSG was formed in HbFeII/GSNO incubates in the
absence of metal chelators, indicating that GSH is the main
source of reducing equivalents under these conditions (Reac-
tion 5). We detected less GSSG than expected by ESI-MS in
HbFeII/GSNO incubates containing DTPA, although we ob-
served 50% GSNO breakdown. This suggested HbFeII as a
possible additional source of reducing equivalents to [Cu(II)-
(DTPA)]2 because related EDTA complexes were shown to be
redox-active with Hb (12). Careful examination of the absorp-
tion (optical and FTIR) spectra revealed the presence of
HbFeIII. Thus, our results indicate that the direct reduction of
GSNO by HbFeII is unlikely to play a role in NO transport in
RBCs. Nonetheless, HbFeII may indirectly provide a source of
electrons for the reductive cleavage of GSNO or other S-nitro-
sothiols in vivo.
The realization that commonly used Cu(I) (neocuproine) and
Cu(II) chelators (EDTA and DTPA) may not always prevent
copper turnover is an important consideration in deciphering
mechanisms of S-nitrosothiol signaling and NO biochemistry in
general. Although neocuproine, a tight binding Cu(I) chelator
(Kd  1.2  10
19 M2) (13, 14), is a better inhibitor than DTPA
of GSNO breakdown (Reaction 4) in Hb-containing solutions,
dialysis of the Hb samples and neocuproine addition were
necessary to obtain negligible GSNO breakdown.
Finally, the prompt changes in HbFeIIO2 on incubation with
GSNO are compared with those observed for the HbFeII incu-
bates. The key results of this comparison are that in the ab-
sence of chelators, S-nitrosation of Cys93 of the oxy protein is
extensive, and this competes with NO capture by the FeIIO2
heme to form HbFeIII and NO3
. In contrast, no S-nitrosation of
the deoxy protein is detected, suggesting that all of the NO
released from GSNO is captured by the FeII heme.
EXPERIMENTAL PROCEDURES
Materials
Human hemoglobin A was obtained from Sigma and used without
further purification. Nanopure water (specific resistance, 18 M	-cm)
obtained from a Millipore Simplicity water purification system and
treated with Chelex-100 (Sigma) to remove trace metal ions was used to
prepare all H2O solutions. The reactions were carried out in 200 mM
sodium phosphate buffer, pH 7.2 (NaPi), prepared from sodium phos-
phate salts (Fisher) in nanopure H2O. Stock solutions of 15 mM dieth-
ylenetriamine-N,N,N,N,N-pentaacetic acid (DTPA; ICN) and 650 M
2,9-dimethyl-1,10-phenanthroline (neocuproine; Sigma) were prepared
in NaPi. Stock solutions of 250 mM GSNO (Cayman) in NaPi were
prepared just before use in a glove bag (Aldrich) under nitrogen, and the
GSNO concentrations were determined spectrophotometrically
(333.5 nm  774 M
1 cm1) (15). GSH and GSSG were obtained from
Sigma, and N2 and NO gases were from Praxair. NO was purged into a
10% KOH water solution before use (16).
Methods
Preparation and Optical Spectroscopy of Hb Samples—Typically 1 g
of lyophilized metHb (HbFeIII) from the bottle was dissolved in 2 ml of
NaPi. After 2 min of centrifugation at 12,000 rpm, the precipitate was
discarded, and the dark red solution of HbFeIII was stored at 4 °C prior
to use. An aliquot (10 l) of the Hb solution was pipetted onto a 13-mm
CaF2 window of a dismountable FTIR type cell (Harrick). The cell was
immediately assembled using a 6-m Teflon spacer (Harrick) and
placed in a custom-made bracket in a Beckman DU 650 UV-visible
spectrophotometer. HbFeIII concentrations were found to be 32 mM in
heme assuming 500 nm  10 mM
1 cm1/heme and 630 nm  4.4 mM
1
cm1/heme (17, 18). This was confirmed by diluting the samples 103-
fold, adding potassium ferricyanide and excess KCN (BDH chemicals),
and reading the absorbance of the CN adduct at 540 nm (540 nm 11.0
mM1 cm1/heme) in a 1-cm cuvette on a Beckman spectrophotometer.
HbFeII was prepared in the glove bag under N2 by treating HbFe
III
with equimolar sodium dithionite (Fisher) (19) followed by desalting on
a 1.6 2.5-cm HiTrap Sephadex G-25 column (Amersham Biosciences),
and the HbFeII concentration was calculated using 555 nm  12.5 mM
1
cm1/heme (20). HbFeIIO2 was prepared from HbFe
II by introducing a
small volume of air into the sample using a syringe; for example, 720 l
of air was added to 200 l of a 32 mM heme sample. A single addition of
O2 in slight excess (8.5 mol of O2/8 mol of heme) yielded fully
oxygenated Hb as indicated by the Soret spectrum recorded following a
5-min equilibration. HbFeIINO and HbFeIIINO were prepared from
HbFeII and HbFeIII on exposure to NO gas. The optical spectra were
recorded using a scan time of 1200 nm/min. Use of the FTIR type cell to
record the optical spectra of the products formed in the HbFeII/GSNO
incubates allowed measurements to be made at close to physiological
concentrations of Hb (2–4 mM) (21).
Preparation of Dialyzed Hb Samples—Approximately 500 mg of
HbFeIII was dissolved in 5 ml of 100 mM Na2EDTA (Sigma), pH 7.0, and
allowed to stand for 30 min. This solution was dialyzed at 4 °C versus
500 ml of 10 mM Na2EDTA, pH 7.0, which was replaced with fresh
solution six times in 24 h. The dialysis was continued versus EDTA-free
H2O, which was replaced with fresh solution 12 times in 48 h. After
dialysis, HbFeIII was lyophilized and dissolved in NaPi to a concentra-
tion of 30 mM heme.
ICP-MS Analysis—A PE Sciex Elan 6000 ICP-MS with a cross-flow
nebulizer and a Scott type spray chamber was used to determine the
amount of copper in the Hb and GSNO samples and in the buffers (see
Table I). The RF power was 1000 W, and the argon flow was 0.85
liter/min, which gave the best sensitivity as determined by the recom-
mended optimization procedure. The optimum lens voltage was deter-
mined by maximizing rhodium sensitivity, and the data were acquired
in the pulse count mode (22). Stock Hb solutions in NaPi were added to
50 l of 30% H2O2 (ACP Chemicals, Inc.) and 500 l of concentrated
HNO3 (OmniTrace Ultra high purity, EM Science) to give a final heme
(iron) concentration of 4.3 mM, and the samples were ashed using a
Bunsen burner. The residue was dissolved in 10 ml of 5% (v/v) HNO3,
and ICP-MS analyses for copper and iron were performed. An internal
standard of 9 nM (0.500 ppb) manganese prepared from a 1000 ppm
manganese standard solution (ACP Chemicals, Inc.) was added to all of
the solutions. The standard curves were prepared by diluting 1000 ppm
copper and iron standard solutions (ACP Chemicals, Inc.) in 5% (v/v)
HNO3 and nanopure water to give 0–8 M (0–0.500 ppm) copper and
0–9 M (0–0.500 ppm) iron. All of the reported ICP-MS data are the
results of at least triplicate experiments, and in all cases the standard
deviations were 5%.
FTIR Analysis—Approximately 20 l of Hb (28 mM heme) in NaPi
was added by syringe onto a 13-mm CaF2 window in the glove bag
under N2 where necessary. The FTIR cell was immediately assembled
with a 250-m Teflon spacer (Harrick), and the spectra were recorded
at 25 °C on a Nicolet Magna-IR 550 spectrometer with a MCT detector
cooled to 77 K and purged with dry air from a Whatman FTIR Purge
(model 75-52). All of the reported spectra are averages of 500 scans
recorded in 5.52 min at a resolution of 2 cm1 using a Happ-Genzel
apodization with a velocity and aperture of 4.4303 cm/s and 2, respec-
tively. Omnic (Nicolet) software was used for subtraction, base-line
correction, smoothing, and Fourier transform self-deconvolution em-
ploying a half-width-at-half-height of 0.6 cm1 and an enhancement (K
factor) of 1. Subtraction of water vapor absorption from the spectra was
performed by the method of Dong et al. (23, 24).
ESI-MS Analysis—Stock Hb solutions (28 mM heme) in NaPi were
diluted 103-fold with H2O to give0.5 g/l protein. The aliquots were
infused into the ESI source of the mass spectrometer (ThermoFinnigan
SSQ 7000) by flow injection from the high performance liquid chroma-
tography (Agilent 1090) using a 100-l loop (but no column) at 50
l/min with 75% CH3CN (0.05% trifluoroacetic acid) as a mobile phase.
Stock (250 mM) GSH, GSNO, and GSSG solutions in 200 mM NaPi, pH
7.2, were diluted 500-fold with H2O and 10-fold to 50 M with 75%
CH3CN (0.05% trifluoroacetic acid), and their mass spectra were ob-
tained as for the Hb solutions.
Multi-component Analysis of the Optical Spectra of Incubates—The
absorbance at a given wavelength is the sum of the absorbances (A) of





















[Y]  zb [Z]  . . . , where x is the molar extinction of X at the selected
wavelength, b is the pathlength (6 m), and [X] is the molar concen-
tration of X. Assuming a limited number of oxidation and coordination
states for iron of Hb, the spectra recorded for the incubates were
mathematically disassembled into those of their components. Absor-
bances at the Soret maxima of the Hb species were used to generate n
Beer’s law expressions, from which the concentrations ([X], [Y], [Z], etc.)
of the n species present in the incubates were obtained. Solutions to the
n equations with n unknowns were obtained using a program at
www.1728.com/indexalg.htm. For the HbFeII/GSNO incubates, absor-
bances were recorded at the Soret maxima of the expected heme species
HbFeIII, HbFeIIINO, HbFeIINO, and HbFeII. The millimolar extinction
coefficients ( in mM1 cm1) and wavelengths (nm; in parentheses)
used are the following: 169 (405), 110 (416), 97 (418), 50 (430) for
HbFeIII; 95.5 (405), 129 (416), 130 (418), 95 (430) for HbFeIINO; 113
(405), 137 (416), 136 (418), and 64 (430) for HbFeIIINO and 62 (405), 92
(416), 99 (418), and 133 (430) for HbFeII. The corresponding values for
the expected iron states in the HbFeIIO2/GSNO incubates are: 169 (405)
and 116 (415) for HbFeIII and 102 (405) and 125 (415) for HbFeIIO2. The
spectra of the components and mixtures were graphed using Origin 6.0
software (Microcal).
RESULTS
ICP-MS Analysis—Because the stability of S-nitrosothiols is
highly dependent on the copper content, all of the solutions
were examined by ICP-MS for trace copper. The results are
summarized in Table I and reveal that 19 M copper was found
in 5 mM Hb (20 mM heme) solutions. This decreased to 2 M
copper following dialysis versus EDTA. NaPi buffer (200 mM)
and the 250 mM stock solutions of GSH and its derivatives were
found to contain 1 M copper (Table I). These values differ
from those reported previously using atomic absorption spec-
troscopy, where 50 M copper was found in solutions contain-
ing 5 mM Hb, but 1 M copper was found in 5 mM dialyzed Hb
as well as in NaPi (4). Because ICP-MS is more sensitive, more
accurate, and did not show matrix effects (as verified using a
manganese internal standard) compared with atomic absorp-
tion spectroscopy (25), the present copper analyses are consid-
ered more reliable.
Optical Absorption Spectra—Fig. 1a compares the spectra of
HbFeII and HbFeIII and their NO adducts in the Soret and
visible regions. As expected, high spin FeII and FeIII hemes
exhibit Soret maxima at 430 and 405 nm, respectively, and
visible bands at 556 nm (FeII) and 500, 540, and 580 nm (FeIII).
Soret maxima are observed at 418 nm (  130 mM1 cm1;
FeIINO) and 416 nm (  137 mM1 cm1; FeIIINO) for the
heme-NO adducts of Hb. The corresponding visible bands are
at 545 and 575 nm (FeIINO) and 540 and 565 nm (FeIIINO).
These values agree with those reported previously (19, 26).
The products formed on mixing HbFeII and GSNO under
anaerobic conditions were directly probed by comparing their
spectra with those in Fig. 1a. Evidence for heme-iron nitrosy-
lation is clearly seen in the Soret and visible bands of the
HbFeII/GSNO incubates without chelators (Fig. 1b). The Soret
maximum blue-shifted from 430 to 418 nm within 5 min of
mixing HbFeII and GSNO, and the visible region resembles
that of HbFeIINO in Fig. 1a. Multi-component analysis of the
5-min spectrum reveals almost complete conversion of HbFeII
to HbFeIINO (Table II). Thus, rapid release of NO from GSNO
occurred in the HbFeII/GSNO sample.
Heme nitrosylation is also evident 5 min after mixing HbFeII
and GSNO in the presence of 200 M DTPA (Fig. 1c). The
extent of nitrosylation is less because the blue shifting of the
Soret maximum is less, and the visible maximum of HbFeII at
556 nm is still evident, indicating that DTPA decreases the
amount of NO released from GSNO. Multi-component analysis
of the spectrum of the 5-min HbFeII/GSNO/DTPA incubate
reveals the presence of 46% HbFeIINO, 44% HbFeII, 8.5%
HbFeIII, and 1% HbFeIIINO (Fig. 2a and Table II). When
HbFeII and GSNO were mixed in the presence of neocuproine,
the spectral changes revealed that significantly less heme ni-
trosylation occurred (Fig. 1d) than in the presence of DTPA,
which was confirmed by multi-component analysis (Table II).
Approximately 33% heme nitrosylation was found in the incu-
bate of dialyzed HbFeII in the absence of chelators (Fig. 1e and
Table II), but the addition of 150 M neocuproine essentially
shut down NO release from GSNO (Fig. 1f) because 98% HbFeII
was found in the 5-min incubate of dialyzed HbFeII/GSNO/
neocuproine (Table II).
To compare the heme species formed in HbFeII/GSNO incu-
bates with those formed in HbFeIIO2/GSNO incubates, the
spectra of the latter were recorded. The Soret spectra of
HbFeIIO2/GSNO (Fig. 3, a and c) reveal that HbFe
III is formed
within 5 min, and multi-component analysis uncovered the
TABLE I
ICP-MS analysis of copper in stock solutions
Samplea Copper
M ppm
5 mM Hbb 19 
 3 1.207 
 0.191
5 mM dialyzed Hbc 2.0 
 0.7 0.127 
 0.045
250 mM GSNO 1.2 
 0.8 0.076 
 0.050
250 mM GSH 1.0 
 0.6 0.063 
 0.038
250 mM GSSG 1.1 
 0.7 0.070 
 0.044
15 mM DTPA 0.7 
 0.3 0.044 
 0.019
650 M neocuproine 1.6 
 0.5 0.102 
 0.032
200 mM NaPi buffer 0.9 
 0.7 0.057 
 0.044
a All stock solutions were prepared in 200 mM sodium phosphate
buffer, pH 7.2
b Human Hb (Sigma) from the bottle. 5 mM Hb contains 20 mM heme.
c Human Hb following dialysis versus EDTA (see “Experimental
Procedures”).
FIG. 1. Effect of 15 mM GSNO and metal chelators on the visible
absorption spectra of 15 mM (heme) HbFeII. a, HbFeIII (solid line),
HbFeIIINO (dotted line), HbFeIINO (dotted and dashed line), and HbFeII
(dashed line). b, HbFeII (dashed line) and HbFeII  GSNO after 5 min
(solid line). c, HbFeII (dashed line) and HbFeIIGSNO 200 M DTPA
after 5 min (solid line). d, HbFeII (dashed line) and HbFeII  GSNO 
150 M neocuproine after 5 min (solid line). e, dialyzed HbFeII (dashed
line) and dialyzed HbFeII  GSNO after 5 min (solid line). f, dialyzed
HbFeII (dashed line) and dialyzed HbFeII  GSNO  150 M neocu-
proine after 5 min (solid line). All of the spectra were recorded in 200
mM sodium phosphate buffer (pH 7.2) at 25 °C in a FTIR cell with a
6-m Teflon spacer using a scan time of 1200 nm/min.




















presence of 46% HbFeIII and 54% HbFeIIO2 (Table II). Sig-
nificantly less HbFeIII formation is detected following mixing of
HbFeIIO2 with GSNO in the presence of DTPA (Fig. 3b). This is
confirmed by multi-component analysis of the 5-min spectrum,
which reveals only 23 and 12% HbFeIII formation in HbFeIIO2/
GSNO incubates containing DTPA and neocuproine, respec-
tively. The formation of HbFeIII likely occurs from the well
characterized reaction of free NO and HbFeIIO2 (27, 28):
HbFeIIO2  NOº HbFeIII  NO3

REACTION 6
FTIR Spectra—FTIR spectroscopy is a valuable probe of
protein thiols because the SH stretching vibration (SH) falls
in a spectral window (2500 cm1) with minimum H2O and
protein absorption (29–31). Although5 mM Hb is necessary to
observe the weak IR (SH) absorption (29–31), comparable Hb
concentrations are found in RBCs (3 mM) (21). The FTIR
spectrum of HbFeII in the (SH) region recorded in the absence
and presence of GSNO and metal chelators (Fig. 4a, spectrum
1) exhibits the three (SH) peaks at 2576, 2563, and 2558 cm1
assigned previously to Cys93, Cys112, and Cys104, respec-
tively (29, 30).
The spectrum of HbFeII plus GSNO (Fig. 4a, spectrum 4)
exhibits a peak for Cys93 (SH) at 2584 cm1, which is close to
that of HbFeIINO (2585 cm1). The (SH) band for Cys93 is
also at 2584 cm1 in the HbFeII/GSNO/DTPA spectrum (Fig.
4a, spectrum 5), but in the presence of both DTPA and neocu-
proine (Fig. 4a, spectrum 2) Cys93 possesses the same (SH)
(2576 cm1) as HbFeII alone (Fig. 4a, spectrum 1). These re-
sults corroborate those from the analysis of the visible spectra,
which revealed that the major Hb species are HbFeIINO and
HbFeII in the 5-min HbFeII/GSNO incubates in the presence of
DTPA and neocuproine, respectively. Furthermore, no evidence
for HbSNO formation is seen in Fig. 4a, because the (SH)
absorption of Cys93 does not appear to lose intensity on expo-
sure to GSNO (Fig. 4a, spectrum 1 versus spectra 2 and 3 and
spectrum 6 versus spectra 4 and 5).
Loss of Cys93 (SH) absorption is clearly evident in Fig. 4b
(spectrum 1). Thus, HbSNO formation does occur in the
HbFeIIO2/GSNO incubates in the absence of metal chelators as
we reported previously (4). The addition of DTPA prevents loss
of Cys93 (SH) intensity, but the spectrum is not identical to
TABLE II
Hb species present in Hb/GSNO incubates based on analysis of their visible spectra
15 mM (heme) Hb plus 15 mM GSNO were incubated at room temperature in 200 mM sodium phosphate buffer, pH 7.2. Spectra were recorded
5 min after the start of the incubation. The wavelengths used in the multi-component analysis were the Soret maxima of the expected components,
and the extinction coefficients are given under “Methods.”
Incubate HbFeII HbFeIII HbFeIINO HbFeIIINO HbFeIIO2
mM mM mM mM mM
HbFeII/GSNO 0.15 14.85







a HbFeII(dial) was dialyzed versus EDTA (see “Methods”).
FIG. 2. Multi-component analysis of the visible absorption
spectra obtained 5 min after mixing 15 mM (heme) HbFeII and 15
mM GSNO. a, observed spectrum from Fig. 1c for HbFeII  GSNO 
DTPA (solid line); sum (line with short dashes) of the spectra of 1.28 mM
HbFeIII (dotted line), 0.16 mM HbFeIIINO (line with dashes and two
dots), 6.97 mM HbFeIINO (line with long dashes), and 6.59 mM HbFeII
(line with dashes and dots). b, observed spectrum from Fig. 1f for
dialyzed HbFeII  GSNO  150 M neocuproine (solid line); sum (line
with short dashes) of the spectra of 0.28 mM HbFeIINO (line with long
dashes) and 14.72 mM HbFeII (dotted and dashed line).
FIG. 3. Effect of 15 mM GSNO and DTPA on the visible absorp-
tion spectra of 15 mM (heme) HbFeIIO2. a, HbFe
IIO2 (dashed line)
and HbFeIIO2  GSNO after 5 min (solid line). b, HbFe
IIO2 (dashed
line) and HbFeIIO2  GSNO  200 M DTPA after 5 min (solid line). c,
observed spectrum from a for HbFeIIO2GSNO after 5 min (solid line);
sum (line with short dashes) of the spectra of 6.85 mM HbFeIII (line with
long dashes) and 8.15 mM HbFeII (dotted line). d, observed spectrum
from b for HbFeIIO2  GSNO  200 M DTPA after 5 min (solid line);
sum (line with short dashes) of the spectra of 3.1 mM HbFeIII (line with






















that of HbFeIIO2 alone (Fig. 4b, spectrum 2 versus spectrum 4).
Direct monitoring of the heme shows 23% conversion of
HbFeIIO2 to HbFe
III within 5 min in the HbFeIIO2/GSNO/
DTPA incubate (Fig. 3 and Table II). Thus, the FTIR data
confirm that DTPA does not prevent release of NO from GSNO
(Reaction 4), but it does inhibit S-nitrosation of Cys93 (Fig. 4b,
spectrum 2 versus spectrum 1). The FTIR spectrum of the
HbFeIIO2/GSNO/neocuproine incubate is essentially identical
to that of HbFeIIO2 alone (Fig. 4b, spectrum 3 versus spectrum
4), which is consistent with the optical results where 88%
HbFeIIO2 was found in the neocuproine incubate (Table II).
Mass Spectral Analysis—ESI-MS was used to probe HbSNO
formation in the HbFeII/GSNO incubates (4). No peak corre-
sponding to S-nitrosation of the -subunit of HbFeII was ob-
served under any conditions with or without metal chelators
(Fig. 5a) or in the dialyzed HbFeII samples. On the other hand,
S-nitrosation of the -subunit was detected following incuba-
tion of HbFeIIO2 with GSNO in the absence of metal chelators
(Fig. 5b) but not in their presence (data not shown). These MS
results support those from FTIR spectroscopy in that HbSNO is
formed only in the HbFeIIO2/GSNO incubates in the absence of
metal chelators (Fig. 4b, spectrum 1).
In the low m/z region of the ESI mass spectra, the low
molecular weight products formed in the HbFeII/GSNO incu-
bates can be monitored. In the absence of metal chelators, a
weak GSNO (m/z 337) and an intense GSSG peak (m/z 613) are
observed (Fig. 6b) that are not present in the spectrum of Hb
alone (Fig. 6a). In mass spectrum of the HbFeII/GSNO/neocu-
proine incubate (Fig. 6d), GSNO is the dominant glutathione
species, and little GSH is present, consistent with decreased
GSNO breakdown in the presence of the Cu(I)-specific chelator.
In Fig. 6c, the GSNO intensity is 50% of that in the presence
of neocuproine, indicating that DTPA is less effective in inhib-
iting the release of NO from GSNO in Hb solutions. However,
a well defined GSSG peak (m/z 613) is not observed in Fig. 6c as
expected if GSH is the major source of electrons for the reduc-
tive cleavage of GSNO (Reactions 4 and 5). A relatively intense
GSH peak persists in Fig. 6c, and also the optical spectra reveal
that HbFeIII is formed in the HbFeII/GSNO/DTPA incubate
(Table II). Because HbFeIII is not observed in the HbFeII incu-
bates in the absence of DTPA, [Cu(II)(DTPA)]2 was added to
a solution of HbFeII to determine whether this complexed form
of copper could oxidize the heme. Multi-component analysis of
the absorption spectrum of 4 M HbFeII and 16 M [Cu(II)-
(DTPA)]2 after 5 min of incubation revealed the presence of
FIG. 4. Effect of 28 mM GSNO and metal chelators on the FTIR
spectra in the (SH) region of 28 mM (heme) Hb. a, spectrum 1,
HbFeII; spectrum 2, HbFeII  GSNO  200 M DTPA  150 M neo-
cuproine; spectrum 3, HbFeII  GSNO  150 M neocuproine; spectrum
4, HbFeII  GSNO; spectrum 5, HbFeII  GSNO  200 M DTPA;
spectrum 6, HbFeIINO. b, spectrum 1, HbFeIIO2  GSNO; spectrum 2,
HbFeIIO2  GSNO  200 M DTPA; spectrum 3, HbFe
IIO2  GSNO 
150 M neocuproine; spectrum 4, HbFeIIO2; spectrum 5, HbFe
IIINO;
spectrum 6, HbFeIII. All of the spectra were recorded in a 250-m
pathlength FTIR cell 5 min after mixing Hb and GSNO in 200 mM
sodium phosphate buffer (pH 7.2) at 25 °C and are the averages of 500
scans at 2-cm1 resolution. Background subtraction, base-line correc-
tion, smoothing, and Fourier transform self-deconvolution were per-
formed on the displayed spectra (see text).
FIG. 5. Deconvolved electrospray mass spectra of the heme-
free Hb subunits following incubation with GSNO. a, HbFeII 
GSNO. b, HbFeIIO2  GSNO. Hb and GSNO were incubated in sodium
phosphate buffer (pH 7.2) for 5 min at 25 °C and diluted 103-fold with
H2O to give 28 M heme (0.5 g/l Hb) and 28 M GSNO. The aliquots
(100 l) were infused into the electrospray source of the mass spectrom-
eter by flow injection at 50 l/min with 75% CH3CN (0.05% trifluoro-
acetic acid) as a mobile phase. The capillary temperature was 180 °C,
and the spray voltage was 4.0 kV. Under the MS conditions, Hb disso-
ciated into free heme and - and -subunits. The unresolved shoulders
on the subunit peaks at high mass were caused by sodium adducts.
FIG. 6. Electrospray mass spectra of glutathione products fol-
lowing incubation with HbFeII. a, HbFeII. b, HbFeII  GSNO. c,
HbFeII  GSNO  200 M DTPA. d, EDTA-dialyzed HbFeII  GSNO 
150 M neocuproine. The experimental conditions are the same as those
given in the legend to Fig. 5. The peaks labeled 24 and 25 were caused
by -globin  24 H and -globin  25 H, respectively. All of the peak
intensities are relative to the (heme  Na) peak at m/z 638 (100%).




















21% HbFeIII (Fig. 7). This can be compared with 19% HbFeIII
formation in the HbFeII/GSNO/DTPA incubates (Table II).
DISCUSSION
Spencer et al. (10) have reported that HbFeII can directly
reduce GSNO and that the released NO is captured by addi-
tional FeII heme. Because the release of NO from GSNO is
known to be Cu(I)-catalyzed (32), we monitored HbFeII/GSNO
incubates by optical and FTIR spectroscopies to probe changes
occurring at the heme and Cys93 centers, respectively. In
addition, the incubates were analyzed by ESI-MS to examine
changes in the mass of the protein and to determine the low
molecular weight species produced.
The optical spectra shown in Fig. 1 clearly reveal that trace
Cu(I) is required for the release of NO from GSNO (Reaction 4).
Essentially no HbFeIINO is formed in the HbFeII/GSNO incu-
bate containing both copper-depleted Hb (i.e. dialyzed Hb in
Table I) and neocuproine. The combined data in Tables I and II
indicate that total inhibition of Cu(I) catalysis of GSNO break-
down requires removal of most of the copper as well as neocu-
proine addition to Hb-containing solutions. Thus, the results
summarized in Table II are not consistent with direct reduction
of GSNO by HbFeII (10) (Reaction 2) when equimolar heme and
GSNO are present. Given the rapid (5 min) Cu(I)-catalyzed
release of NO from GSNO (Fig. 1b), it is likely that copper-
catalyzed reductive cleavage of GSNO also occurs in vivo.
The next question that arises is, of course, what is the source
of reducing equivalents to regenerate Cu(I) following electron
transfer to GSNO to release NO (Reaction 4)? Possible electron
donors to Cu(II) are GSH (Reaction 5) and HbFeII. With GSH
as a donor, two molecules of NO would be released or two heme
FeIINO adducts would be formed per molecule of GSSG pro-
duced. The mass spectrum reveals extensive formation of
GSSG in the HbFeII/GSNO incubates in the absence of chela-
tors (Fig. 6b). Although a peak corresponding to its Na adduct
occurs at m/z 635, the expected GSSG peak at m/z 613 is not
clearly evident in HbFeII/GSNO incubates containing DTPA.
Nonetheless, GSNO does release NO, as evidenced by the loss
of GSNO peak intensity relative to the base peak at m/z 638
(Fig. 6, c versus d) and the formation of HbFeIINO (Fig. 1c and
Table II). Thus, reduction of [Cu(II)(DTPA)]2 by HbFeII was
considered, which would account for the HbFeIII absorbance
seen in Fig. 2a. From Table II, 7.13 mM NO is released (6.97 mM
HbFeIINO and 0.16 mM HbFeIIINO) from the 15 mM GSNO
present in the HbFeII/GSNO/DTPA incubate. If all of the re-
ducing equivalents were to come from GSH oxidation (Reaction
5), then 3.56 mM GSSG should be produced. However, HbFeII
oxidation provides 1.44 milliequivalents of reductant (1.28 mM
HbFeIII and 0.16 mM HbFeIIINO), which would decrease the
concentration of GSSG produced to 2.84 mM. This is approxi-
mately one-third of the GSSG produced in HbFeII/GSNO incu-
bates where a strong GSSG peak is observed at m/z 613. The
lower than expected intensity of the GSSG (m/z 613) peak in
Fig. 6c is attributed to ion suppression. The production of
HbFeIII in the HbFeII incubates in the presence but not the
absence of DTPA (Table II) suggested that [Cu(II)(DTPA)]2
may accept an electron from HbFeII, which was confirmed. The
addition of authentic [Cu(II)(DTPA)]2 to HbFeII led to oxida-
tion of 21% of the heme (Fig. 7). Electron transfer between
[Fe(II)(EDTA)]2 and HbFeIII has been reported previously
(12).
No loss of (SH) intensity was detected by FTIR when HbFeII
was treated with GSNO with or without metal chelators (Fig.
4a). This is consistent with the proposal that the allosteric
transition of Hb controls Cys93 S-nitrosation (33). The FTIR
results also show that Cu(I) is required for HbFeIINO forma-
tion because neocuproine inhibited blue shifting of the Cys93
(SH) peak (Fig. 4a, spectra 2 and 3) that accompanies heme
nitrosylation (29). The reactions in the HbFeII/GSNO incubates
reported here are shown in Scheme 1. Clearly the oxidation of
HbFeII by [Cu(II)(DTPA)]2 is unlikely to be of importance in
vivo, but the requirement of copper for NO release from GSNO
shown in Scheme 1 could well have physiological relevance.
The key result that copper is also required for S-nitrosation
of Cys93 of HbFeIIO2 (4) can be deduced from Figs. 4b and 5b.
S-Nitrosation of Cys93 is observed only in the absence of metal
chelators (Fig. 4b, spectrum 1, and Fig. 5b). Thus, we propose
Scheme 2 for the reactions of NO with HbFeIIO2. NO is tar-
geted to Cys93 in the absence of chelators, but in the presence
of DTPA, all of the NO released from GSNO is targeted to the
FeIIO2 heme (Figs. 3 and 4b) and converted to NO3
 (Reaction
6). Scheme 2 predicts that efficient Cu(II)–catalyzed S-nitro-
sation of Cys93 will preserve the biological activity of NO by
preventing its conversion to nonvasoactive NO3
. The capture of
NO by HbFeII (Scheme 1) should not lead to loss of its vasoac-
tive power as long as FeII-NO adduct formation is reversible on
a physiologically relevant time scale. It has been proposed that
the FeII heme centers of partially oxygenated Hb, as found in
the RBC (1), have a much lower affinity for NO than fully
deoxygenated HbFeII (9). Thus, copper control of NO reactivity
with Hb, plus weaker binding of NO to HbFeII in vivo than in
vitro, could explain why RBC Hb does not act a sink for most of
the NO produced in the vascular system. A possible copper
catalyst in vivo is copper-zinc superoxide dismutase, which is
abundant in the RBC (34).
It is of interest to compare the extent of the prompt changes
in HbFeII and HbFeIIO2 on incubation with GSNO. When 15
mM GSNO is incubated with 15 mM (heme) HbFeII in the
absence of metal chelators, 99% is converted to HbFeIINO
within 5 min, whereas only 46% of HbFeIIO2 is converted to
SCHEME 2
FIG. 7. Visible absorption spectra of 4 M (heme) HbFeII with
16 M [Cu(II)(DTPA)]2. Dashed line, HbFeII; solid line, HbFeII 
[Cu(II)(DTPA)]2 after 5 min. [Cu(II)(DTPA)]2 was prepared by mix-
ing equimolar solutions of CuSO4 and DTPA. The experimental details























HbFeIII under the same conditions. This is easy to understand
when we consider that 7.5 mM NO released from GSNO was
targeted to Cys93 in HbFeIIO2 but not in HbFe
II (Figs. 4 and
5). In the DTPA incubates 44% HbFeII versus 77% HbFeIIO2
remain, and in neocuproine incubates 75% HbFeII versus 88%
HbFeIIO2 remain after the same 5-min period. Clearly, the
increased stability of the Hb reactants in the presence of metal
chelators is due to inhibition of GSNO breakdown, but the
lower consumption of HbFeIIO2 relative to HbFe
II cannot be
attributed to NO trapping by Cys93 in the former because this
does not occur in the presence of chelators (Fig. 4b). More
efficient NO trapping by HbFeII (35) than by HbFeIIO2 (k 
3–5  107 M1 s1 for Reaction 6) (36) would give rise to the
higher HbFeII consumption in the incubates. Also, the reaction
of NO with any free O2 in the HbFe
IIO2 incubate would de-
crease the amount of HbFeIIO2 consumed.
In this work we also examined the spectra of the HbFeII/
GSNO incubates after 1 h. The results obtained indicate that
the prompt products undergo further reaction over longer
times. For example, the Soret maximum after 1 h of HbFeII/
GSNO incubate still shows a maximum at 418 nm but with
decreased intensity (data not shown). Because the spectrum of
authentic HbFeIINO in the absence of any glutathione-derived
species is stable for 1 h, the HbFeIINO initially formed must
react with some reagent in the incubate.2 The Soret maximum
of the HbFeII/GSNO/DTPA incubate after 1 h (data not shown)
is blue-shifted (409 nm) from that at 5 min (411 nm) (Fig. 1c).
We initially attributed this blue shift to increased HbFeIINO
formation caused by NO-driven reduction of HbFeIII using re-
ducing equivalents from GSH. However, the addition of GSH to
authentic HbFeIIINO also gave rise to a Soret maximum at 411
nm and not the expected HbFeIINO peak at 418 nm. The
biological relevance of these slow reactions is questionable be-
cause, for example, any HbFeIII formed in the RBC would be
rapidly converted to HbFeII by methemoglobin reductase (37).
CONCLUSIONS
The results reported here provide insight into the mecha-
nism of heme nitrosylation following mixing of HbFeII with
GSNO. The data presented are inconsistent with direct reduction
of GSNO by HbFeII but are consistent with catalysis of GSNO
breakdown by trace copper and free NO generation in the reac-
tions. Because HbFeII is stable in the presence of GSNO when
free copper is rigorously excluded from the system, direct reduc-
tion of GSNO by HbFeII is unlikely to be of biological significance.
Trace copper also controls targeting of NO released from GSNO
to the Cys93 and FeIIO2 centers of HbFe
IIO2. Thus, we conclude
that copper catalysis of S-nitrosation and S-denitrosation plays a
key role in preserving the vasoactivity of NO in the RBC.
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